US · Healthcare · Medical Devices
EPS came in at -0.46 against a street estimate of -0.39 — a miss of 17.9%.
Analysts rate Procept Biorobotics Corp a hold (5 buy, 9 hold, 1 sell out of 15) with an average price target of $22.25.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.50% |
| T. Rowe Price Investment Management,Inc. | 5.70% |
| BNP Paribas Investment Partners SA | 4.93% |
| Vanguard Portfolio Management, LLC | 4.41% |
| Vanguard Capital Management, LLC | 4.30% |
| Chicago Capital LLC | 3.62% |
| State Street Corp | 2.82% |
| Geode Capital Management, LLC | 2.59% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $98,291 thousand, up from $83,327 thousand in the third quarter of 2025. • Nine-month 2026 revenue | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $98.3 million, up 18% from the prior-year period. • U.S. procedures exceeded 13,400, up approximately 22%. • | 2026-11-04 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • On October 2, 2026, PROCEPT BioRobotics increased its board size from nine members to ten members. • Dr. Michael Mack was app | 2026-10-02 |
| Material agreement · Q3 2026 PROCEPT BIOROBOTICS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: PROCEPT BioRobotics Corporation (Ticker: PRCT, Nasdaq) • Filing Date: | 2026-09-24 |
| Quarterly report · Q2 2026 PROCEPT BIOROBOTICS CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (6M 2026): $177.6 million, up 19.7% vs $148.3 million (6M 2025) • | 2026-08-05 |
| Results announced · Q3 2026 PROCEPT BIOROBOTICS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q2 2026: $94.5 million, up 19% year-over-year • U.S. procedures Q2 202 | 2026-08-04 |
| Shareholder vote results · Q2 2026 PROCEPT BIOROBOTICS CORPORATION — FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 9, 2026 • Total votes cast for director n | 2026-06-10 |
| Quarterly report · Q1 2026 PROCEPT BIOROBOTICS CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $83.1 million (Q1 2026) vs $69.2 million (Q1 2025) — growth of 20 | 2026-04-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Procept Biorobotics Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.